Since MIP-1α, MIP-1β, MCP-1 are known chemokines that recruit immune cells to inflammatory sites, berberine may work in the initial phase of NAFLD/NASH by preventing inflammatory cell infiltration into the liver. Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.